CXCL5 as a potential novel prognostic factor in early stage non-small cell lung cancer: results of a study of expression levels of 23 genes

[1]  Rebecca Finch,et al.  Multiple testing problems in pharmaceutical statistics. , 2014, Pharmaceutical statistics.

[2]  T. Ishiko,et al.  Identification of CXCL5/ENA‐78 as a factor involved in the interaction between cholangiocarcinoma cells and cancer‐associated fibroblasts , 2012, International journal of cancer.

[3]  Y. Toiyama,et al.  CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer. , 2012, European journal of cancer.

[4]  I. Dialsingh.  Multiple testing problems in pharmaceutical statistics , 2011 .

[5]  Borna Mehrad,et al.  Chemokines as mediators of tumor angiogenesis and neovascularization. , 2011, Experimental cell research.

[6]  M. Burdick,et al.  Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. , 2011, The American journal of pathology.

[7]  S. Motoyama,et al.  Expression of the chemokine receptor CXCR4 correlates with a favorable prognosis in patients with adenocarcinoma of the lung. , 2010, Lung cancer.

[8]  Richard Simon,et al.  Gene expression-based prognostic signatures in lung cancer: ready for clinical use? , 2010, Journal of the National Cancer Institute.

[9]  A. Griffioen,et al.  Integrin expression profiling identifies integrin alpha5 and beta1 as prognostic factors in early stage non-small cell lung cancer , 2010, Molecular Cancer.

[10]  Marcin Skrzypski,et al.  An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non–Small-Cell Lung Cancer , 2009, Clinical Cancer Research.

[11]  Edward S. Kim,et al.  Cyclic AMP-Responsive Element Binding Protein– and Nuclear Factor-κB–Regulated CXC Chemokine Gene Expression in Lung Carcinogenesis , 2008, Cancer Prevention Research.

[12]  C. Rubie,et al.  Enhanced ENA-78 and IL-8 Expression in Patients with Malignant Pancreatic Diseases , 2008, Pancreatology.

[13]  J. Van Damme,et al.  The role of CXC chemokines and their receptors in cancer. , 2008, Cancer letters.

[14]  Ichiro Yoshino,et al.  Aberrant methylation of CXCL12 in non-small cell lung cancer is associated with an unfavorable prognosis. , 2008, International journal of oncology.

[15]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[16]  Patrick Royston,et al.  Multivariable Model-Building: A Pragmatic Approach to Regression Analysis based on Fractional Polynomials for Modelling Continuous Variables , 2008 .

[17]  Cornelis J H van de Velde,et al.  Disrupted Expression of CXCL5 in Colorectal Cancer Is Associated with Rapid Tumor Formation in Rats and Poor Prognosis in Patients , 2008, Clinical Cancer Research.

[18]  H. D. Vanguilder,et al.  Twenty-five years of quantitative PCR for gene expression analysis. , 2008, BioTechniques.

[19]  J. Soria,et al.  Gene expression profiling of non-small-cell lung cancer , 2008, Expert review of molecular diagnostics.

[20]  A. Chinnaiyan,et al.  CXCL5 promotes prostate cancer progression. , 2008, Neoplasia.

[21]  M. Skrzypski.  Quantitative reverse transcriptase real-time polymerase chain reaction (qRT-PCR) in translational oncology: lung cancer perspective. , 2008, Lung cancer.

[22]  Stefan Gräber,et al.  ELR+ CXC chemokine expression in benign and malignant colorectal conditions , 2008, BMC Cancer.

[23]  Igor Jurisica,et al.  Three-gene prognostic classifier for early-stage non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. Vacher,et al.  CXC chemokines located in the 4q21 region are up-regulated in breast cancer. , 2007, Endocrine-related cancer.

[25]  N. Tanaka,et al.  Up-regulation of CXC chemokines and their receptors: implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis. , 2007, Human pathology.

[26]  Marcin Skrzypski,et al.  Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. , 2007, The Lancet. Oncology.

[27]  A. Sadanandam,et al.  Chemokines in tumor angiogenesis and metastasis , 2007, Cancer and Metastasis Reviews.

[28]  Leah E. Mechanic,et al.  Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. , 2007, Journal of the National Cancer Institute.

[29]  Kyung Hwa Park,et al.  CXCL5 overexpression is associated with late stage gastric cancer , 2007, Journal of Cancer Research and Clinical Oncology.

[30]  D. Beer,et al.  Diversity of the angiogenic phenotype in non-small cell lung cancer. , 2007, American journal of respiratory cell and molecular biology.

[31]  S. Mocellin,et al.  Complementary techniques: validation of gene expression data by quantitative real time PCR. , 2007, Advances in experimental medicine and biology.

[32]  Zhifu Sun,et al.  A Gene Expression Signature Predicts Survival of Patients with Stage I Non-Small Cell Lung Cancer , 2006, PLoS medicine.

[33]  G. Strauss.  Management of early-stage lung cancer: past, present, and future adjuvant trials. , 2006, Oncology.

[34]  S. Mukherjee,et al.  A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. , 2006, The New England journal of medicine.

[35]  Yi Zhang,et al.  Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. , 2006, Cancer research.

[36]  D. Harmer,et al.  Evaluation of low density array technology for quantitative parallel measurement of multiple genes in human tissue , 2006, BMC Genomics.

[37]  J. Weinstein,et al.  Biomarkers in Cancer Staging, Prognosis and Treatment Selection , 2005, Nature Reviews Cancer.

[38]  Y. Yatabe,et al.  Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Diane D. Liu,et al.  Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  M. Iannettoni,et al.  Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  David E. Misek,et al.  Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.

[42]  Ana Ivelisse Avilés,et al.  Linear Mixed Models for Longitudinal Data , 2001, Technometrics.

[43]  M. Iannettoni,et al.  Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. , 1998, The Journal of clinical investigation.

[44]  M Schemper,et al.  A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.

[45]  R. Strieter,et al.  Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8 , 1991, The Journal of experimental medicine.